NEW YORK (GenomeWeb) – Biocartis announced today that it has submitted its Idylla molecular diagnostics platform to the US Food and Drug Administration for 510(k) clearance, along with a respiratory panel from partner Janssen Diagnostics to detect influenza and respiratory syncytial virus using the Idylla platform.